Critical role for prokineticin 2 in CNS autoimmunity

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 3, 2015, Pages e95-

  Abou Hamdan, Mhamad ^a   Costanza, Massimo ^a   Fontana, Elena ^b   Di Dario, Marco ^c   Musio, Silvia ^a   Congiu, Cenzo ^d   Onnis, Valentina ^d   Lattanzi, Roberta ^e   Radaelli, Marta ^c   Martinelli, Vittorio ^c   Salvadori, Severo ^f   Negri, Lucia ^e   Poliani, Pietro Luigi ^b   Farina, Cinthia ^c   Balboni, Gianfranco ^d   Steinman, Lawrence ^g   Pedotti, Rosetta ^a,g  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; MESSENGER RNA; MYELIN; PEPTIDE; PROKINETICIN 2; UNCLASSIFIED DRUG; GROWTH FACTOR; PC 1; PC 7; TRIAZINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; BIOLOGICAL FUNCTIONS; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATORY INFILTRATE; LYMPH NODE CELL; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD; SPLEEN CELL; T LYMPHOCYTE; ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; DEMYELINATION; DRUG EFFICACY; GENETIC TRANSCRIPTION; HUMAN CELL; IC50; IN VIVO STUDY; NERVOUS SYSTEM INFLAMMATION; PK2 GENE; TH1 CELL; TH17 CELL; UPREGULATION;

EID: 84945195103     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000095     Document Type: Article

References (39)

1. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009;9:393-407.
2. Steinman L. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol 2014;32:257-281.
3. Steinman L, Merrill JT, McInnes IB, Peakman M. Optimization of current and future therapy for autoimmune diseases. Nat Med 2012;18:59-65.
4. LeCouter J, Zlot C, Tejada M, Peale F, Ferrara N. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci USA 2004;101: 16813-16818.
5. Giannini E, Lattanzi R, Nicotra A, et al. The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory gran-ulocytes and modulates inflammatory pain. Proc Natl Acad Sci USA 2009;106:14646-14651.
6. Cheng MY, Bullock CM, Li C, et al. Prokineticin 2 transmits the behavioural circadian rhythm of the suprachias-matic nucleus. Nature 2002;417:405-410.
7. LeCouter J, Kowalski J, Foster J, et al. Identification of an angiogenic mitogen selective for endocrine gland endothe-lium. Nature 2001;412:877-884.
8. Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007;450: 825-831.
9. Ng KL, Li JD, Cheng MY, Leslie FM, Lee AG, Zhou QY. Dependence of olfactory bulb neurogenesis on prokineti-cin 2 signaling. Science 2005;308:1923-1927.
10. Melchiorri D, Bruno V, Besong G, et al. The mammalian homologue of the novel peptide Bv8 is expressed in the central nervous system and supports neuronal survival by activating the MAP kinase/PI-3-kinase pathways. Eur J Neurosci 2001;13:1694-1702.
11. Pitteloud N, Zhang C, Pignatelli D, et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2007;104:17447-17452.
12. Franchi S, Giannini E, Lattuada D, et al. The prokineticin receptor agonist Bv8 decreases IL-10 and IL-4 production in mice splenocytes by activating prokineticin receptor-1. BMC Immunol 2008;9:60.
13. Martucci C, Franchi S, Giannini E, et al. Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages. Br J Pharmacol 2006;147:225-234.
14. Negri L, Lattanzi R Bv8/PK2 and prokineticin receptors: a druggable pronociceptive system. Curr Opin Pharmacol 2011;12:62-66.
15. Cheng MY, Lee AG, Culbertson C, et al. Prokineticin 2 is an endangering mediator of cerebral ischemic injury. Proc Natl Acad Sci USA 2012;109:5475-5480.
16. Monnier J, Samson M. Cytokine properties of prokineticins. FEBS J 2008;275:4014-4021.
17. Dorsch M, Qiu Y, Soler D, et al. PK1/EG-VEGF induces monocyte differentiation and activation. J Leukoc Biol 2005;78:426-434.
18. Zhong C, Qu X, Tan M, Meng YG, Ferrara N. Characterization and regulation of bv8 in human blood cells. Clin Cancer Res 2009;15:2675-2684.
19. Watson RP, Lilley E, Panesar M, et al. Increased prokineticin 2 expression in gut inflammation: role in visceral pain and intestinal ion transport. Neurogastroenterol Motil 2012;24:65-75, e12.
20. Costanza M, Musio S, Abou-Hamdan M, Binart N, Pedotti R Prolactin is not required for the development of severe chronic experimental autoimmune encephalomyelitis. J Immunol 2013;191:2082-2088.
21. Pedotti R, Mitchell D, Wedemeyer J, et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol 2001;2:216-222.
22. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-846.
23. Congiu C, Onnis V, Deplano A, et al. A new convenient synthetic method and preliminary pharmacological char-acterization of triazinediones as prokineticin receptor antagonists. Eur J Med Chem 2014;81:334-340.
24. Balboni G, Lazzari I, Trapella C, et al. Triazine compounds as antagonists at Bv8-prokineticin receptors. J Med Chem 2008;51:7635-7639.
25. Maftei D, Marconi V, Florenzano F, et al. Controlling the activation of the Bv8/prokineticin system reduces neuro-inflammation and abolishes thermal and tactile hyperalgesia in neuropathic animals. Br J Pharmacol 2014;171: 4850-4865.
26. King IL, Dickendesher TL, Segal BM. Circulating Ly-6C1 myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009;113:3190-3197.
27. Qu X, Zhuang G, Yu L, Meng G, Ferrara N. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b1Gr11 cells: key role of Stat3 signaling. J Biol Chem 2012;287:19574-19584.
28. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8:500-508.
29. Openshaw H, Stuve O, Antel JP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000;54:2147-2150.
30. Jacob A, Saadoun S, Kitley J, et al. Detrimental role of granulocyte-colony stimulating factor in neuromyelitis op-tica: clinical case and histological evidence. Mult Scler 2012;18:1801-1803.
31. Zavala F, Abad S, Ezine S, Taupin V, Masson A, Bach JF. G-CSF therapy of ongoing experimental allergic encepha-lomyelitis via chemokine-and cytokine-based immune deviation. J Immunol 2002;168:2011-2019.
32. Xin H, Lu R, Lee H, et al. G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells. J Biol Chem 2013;288:13842-13849.
33. Egwuagu CE. STAT3 in CD41 T helper cell differentiation and inflammatory diseases. Cytokine 2009;47: 149-156.
34. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441: 235-238.
35. Mauer J, Chaurasia B, Goldau J, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 2014;15:423-430.
36. Fang XX, Jiang XL, Han XH, Peng YP, Qiu YH. Neuro-protection of interleukin-6 against NMDA-induced neu-rotoxicity is mediated by JAK/STAT3, MAPK/ERK, and PI3K/AKT signaling pathways. Cell Mol Neurobiol 2013; 33:241-251.
37. Jung JE, Kim GS, Chan PH. Neuroprotection by interleukin-6 is mediated by signal transducer and activator of transcription 3 and antioxidative signaling in ische-mic stroke. Stroke 2011;42:3574-3579.
38. Kostic M, Zivkovic N, Stojanovic I. Multiple sclerosis and glutamate excitotoxicity. Rev Neurosci 2013;24:71-88.
39. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neu-rol 2012;8:647-656.